Evaluation of an eyelid cleansing wipes for dry eye management.

  • Research type

    Research Study

  • Full title

    Evaluation of an Eyelid Cleansing Wipes for Meibomian Glands Dysfunction Management

  • IRAS ID

    246536

  • Contact name

    Ali Mearza

  • Contact email

    ali@eyedoc.eu.com

  • Sponsor organisation

    Laboratoires Horus Pharma

  • Duration of Study in the UK

    0 years, 8 months, 9 days

  • Research summary

    Dry eye is a complex condition for which numerous management products have been developed to deal with the many aetiologies resulting in the condition. Most products are in the form of eyedrops or eyegel addressing the destabilization of the tear film, while other address the inflammatory component of dry eye. Sodium hyaluronate (Hyaluronate Acid (HA)) are used extensively in patients complaining of dry eye.
    Horus Pharma has a range of products for dry eye sufferers with meibomian glands anomalies to use for home treatment.
    ILAST® WIPES, 0.2% sodium hyaluronate and allantoin, CE marked cleansing wipes for eyelid hygiene manufactured by Horus Pharma is designed for cleaning eyelids, particularly the inflamed eyelid margin. By removing the deposits, secretions or crusts present on the eyelids and the roots of the eyelashes, the clean eyelids will lessen the dry eye symptoms. The rationale for the proposed study is to determine the clinical performance of ILAST® Wipes by quantifying the improvement in dry eye symptoms and meibomian gland status after four weeks using the study product. The results of this study will be used to power future comparative studies. Thirty symptomatic dry eye participants will be enrolled. There will be two study visits over a month period. Participants will be using the ILAST® Wipes eyelid cleansing wipes every day in the morning upon waking and at night prior to sleep by applying it on closed eyelid skin and eyelid margin.

  • REC name

    London - Riverside Research Ethics Committee

  • REC reference

    18/LO/0809

  • Date of REC Opinion

    27 Apr 2018

  • REC opinion

    Favourable Opinion